blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3331543

EP3331543 - CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  15.02.2020
Database last updated on 14.11.2024
FormerRequest for examination was made
Status updated on  11.05.2018
FormerThe international publication has been made
Status updated on  11.02.2017
Most recent event   Tooltip13.08.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000 / US
[2018/24]
Inventor(s)01 / HERRMANN, Andreas
3362 Caminito Luna Nueva
Del Mar, CA 92014 / US
02 / YU, Hua
123 S. Oakhart Drive
Glendora, CA 91741 / US
 [2018/26]
Former [2018/24]01 / HERRMANN, Andreas
500 S. El Molino
Pasadena, CA 91101 / US
02 / YU, Hua
123 S. Oakhart Drive
Glendora, CA 91741 / US
Representative(s)HGF
HGF Limited
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2018/24]HGF Limited
Saviour House
9 St. Saviourgate
York YO1 8NQ / GB
Application number, filing date16833941.405.08.2016
[2018/24]
WO2016US45817
Priority number, dateUS201562202006P06.08.2015         Original published format: US 201562202006 P
[2018/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017024238
Date:09.02.2017
Language:EN
[2017/06]
Type: A1 Application with search report 
No.:EP3331543
Date:13.06.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 09.02.2017 takes the place of the publication of the European patent application.
[2018/24]
Search report(s)International search report - published on:US09.02.2017
(Supplementary) European search report - dispatched on:EP18.02.2019
ClassificationIPC:A61K38/00, A61K38/14, A61K47/00, C07K16/00, C07K16/18, // C12N15/11, A61K39/00
[2019/12]
CPC:
C07K16/468 (EP,US); A61K38/00 (EP,US); A61K38/14 (EP,US);
A61K47/549 (US); A61K47/6843 (US); A61K47/6851 (US);
A61K47/6871 (US); A61K47/6879 (US); A61K47/6889 (US);
A61P35/00 (EP,US); C07K16/00 (EP,US); C07K16/18 (EP,US);
C07K16/30 (US); C07K16/40 (US); C12N15/11 (EP,US);
A61K2039/505 (EP,US); C07K2317/24 (US); C07K2317/31 (EP,US);
C07K2317/40 (US); C07K2317/622 (US); C07K2317/77 (EP,US);
C12N2310/18 (EP,US); C12N2310/315 (EP,US); C12N2310/3513 (EP,US) (-)
Former IPC [2018/24]A61K38/00, A61K38/14, A61K39/00, A61K47/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/24]
TitleGerman:ZELLPENETRIERENDE PROTEINANTIKÖRPERKONJUGATE UND VERFAHREN ZUR VERWENDUNG[2018/24]
English:CELL PENETRATING PROTEIN-ANTIBODY CONJUGATES AND METHODS OF USE[2018/24]
French:CONJUGUÉS DE PÉNÉTRATION CELLULAIRE FORMÉS DE PROTÉINE ET D'ANTICORPS ET MÉTHODES D'UTILISATION[2018/24]
Entry into regional phase15.02.2018National basic fee paid 
15.02.2018Search fee paid 
15.02.2018Designation fee(s) paid 
15.02.2018Examination fee paid 
Examination procedure15.02.2018Examination requested  [2018/24]
15.02.2018Date on which the examining division has become responsible
17.09.2019Amendment by applicant (claims and/or description)
19.02.2020Despatch of a communication from the examining division (Time limit: M04)
29.06.2020Reply to a communication from the examining division
23.12.2020Despatch of a communication from the examining division (Time limit: M04)
23.04.2021Reply to a communication from the examining division
Fees paidRenewal fee
10.08.2018Renewal fee patent year 03
15.08.2019Renewal fee patent year 04
13.08.2020Renewal fee patent year 05
13.08.2021Renewal fee patent year 06
15.06.2022Renewal fee patent year 07
24.08.2023Renewal fee patent year 08
13.08.2024Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2009012356  (GEN HOSPITAL CORP [US], et al) [X] 1-3,10-12,14,15 * figure 1 * * the whole document *;
 [A]WO2009126933  (ALNYLAM PHARMACEUTICALS INC [US], et al) [A] 1-15 * figure 1 ** the whole document *;
 [A]WO2012030683  (MERCK SHARP & DOHME [US], et al) [A] 1-15 * page 57; claims 1-5 * * the whole document *;
 [I]WO2015031837  (HOPE CITY [US], et al) [I] 1-15 * the whole document *
International search[A]US2011027300  (KAMIL UGURBIL [DE], et al) [A] 1-59 * entire document *;
 [A]US2013137644  (ALLUIS BERTRAND [FR], et al) [A] 1-59 * entire document *;
 [A]US2014371302  (AFEYAN NOUBAR B [US], et al) [A] 1-59 * entire document *;
 [A]WO2015031837  (HOPE CITY [US], et al) [A] 1-59 * entire document *;
 [PX]WO2016115500  (HOPE CITY [US]) [PX] 1-59* entire document *
by applicantEP0003089
 EP0173494
 WO8702671
 US4676980
 US4816567
 US4861760
 US4911920
 US4946778
 WO9100360
 US5034506
 WO9200373
 WO9308829
 US5212162
 US5235033
 US5403841
 US5530101
 US5545807
 US5545806
 US5569825
 US5585089
 US5625126
 US5633425
 US5661016
 US5693761
 US5693762
 US5777085
 US5859205
 US6180370
 US6210671
 US6329511
 WO2009012356
 WO2015031837
    - LONBERG et al., Nature, (19940000), vol. 368, pages 812 - 859
    - "Carbohydrate Modifications in Antisense Research", ECKSTEIN, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press
    - "UniProt", Database accession no. Q048648
    - "NCBI", Database accession no. GI:83700231
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - KOHLERMILSTEIN, Nature, (19750000), vol. 256, pages 495 - 497
    - KOZBOR et al., Immunology Today, (19830000), vol. 4, page 72
    - "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", ARNON et al., Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., (19850000), pages 243 - 56
    - MARKS et al., Bio/Technology, (19920000), vol. 10, pages 779 - 783
    - FISHWILD et al., Nature Biotechnology, (19960000), vol. 14, pages 826 - 51
    - LONBERGHUSZAR, Intern. Rev. Immunol., (19950000), vol. 13, pages 65 - 93
    - MARKS et al., Biotechnology, (19920000), vol. 10, pages 779 - 783
    - TRAUNECKER et al., EMBO J., (19910000), vol. 10, pages 3655 - 3659
    - SURESH et al., Methods in Enzymology, vol. 121, page 210
    - JONES et al., Nature, (19860000), vol. 321, pages 522 - 525
    - VERHOEYEN et al., Science, (19880000), vol. 239, pages 1534 - 1536
    - WINTERMILSTEIN, Nature, (19910000), vol. 349, page 293
    - MORRISON et al., PNAS USA, (19840000), vol. 81, pages 6851 - 6855
    - RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 327
    - MORRISONOI, Adv. Immunol., (19880000), vol. 44, pages 65 - 92
    - PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596
    - PADLAN, Molec. Immun., (19910000), vol. 28, pages 489 - 498
    - PADLAN, Molec. Immun., (19940000), vol. 31, no. 3, pages 169 - 217
    - "Antibodies For Drug Delivery", HELLSTROM et al., Controlled Drug Delivery, Marcel Dekker, Inc., (19870000), pages 623 - 53
    - THORPE et al., "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", Monoclonal Antibodies '84: Biological And Clinical Applications, (19850000), pages 475 - 506
    - THORPE et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", Immunol. Rev., (19820000), vol. 62, doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872

DOI:   http://dx.doi.org/10.1111/j.1600-065X.1982.tb00392.x
    - AL-MUHAMMED, J. Microencapsul., (19960000), vol. 13, pages 293 - 306
    - CAS , no. 58-85-5
    - "MODIFICATION OF PROTEINS", FEENEY et al., Advances in Chemistry Series, American Chemical Society, (19820000), vol. 198
    - DICKSON, Methods Mol. Biol., (20080000), vol. 461, pages 735 - 44
    - NICKELS, Methods, (20090000), vol. 47, no. 1, pages 53 - 62
    - ZINCHUK et al., Acta Histochem. Cytochem., (20070000), vol. 40, no. 4, pages 101 - 11
    - LIEBERMAN, Pharmaceutical Dosage Forms, (19920000), vol. 1-3
    - PICKAR, Dosage Calculations
    - RAO, J. Biomater Sci. Polym. Ed., (19950000), vol. 7, pages 623 - 645
    - GAO, Pharm. Res., (19950000), vol. 12, pages 857 - 863
    - EYLES, J. Pharm. Pharmacol., (19970000), vol. 49, pages 669 - 674
    - CHONN, Curr. Opin. Biotechnol., (19950000), vol. 6, pages 698 - 708
    - OSTRO, Am. J. Hosp. Pharm., (19890000), vol. 46, pages 1576 - 1587
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.